Adamis Pharmaceuticals Corp (ADMP)


Stock Price Forecast

Dec. 8, 2022


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Adamis Pharmaceuticals Corp chart...

About the Company

Adamis Pharmaceuticals Corporation is a specialty biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease. The company's SYMJEPI (epinephrine) Injection products are approved by the FDA for use in the emergency treatment of acute allergic reactions, including anaphylaxis. Adamis' naloxone injection product candidate, ZIMHI, for the treatment of opioid overdose is currently under FDA review. Adamis is developing additional products, including treatments for acute respiratory diseases, such as COVID-19, influenza, asthma, and COPD. The company's subsidiary, US Compounding Inc., compounds sterile prescription drugs, and certain nonsterile drugs for human and veterinary use by hospitals, clinics, surgery centers, and vet clinics throughout most of the United States. Forward Looking Statements

CEO

Dennis Carlo

Exchange

NASDAQ

Website

www.adamispharmaceuticals.com

$-16M

Total Revenue

130

Employees

$29M

Market Capitalization

-0.20

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $ADMP News

Adamis Pharmaceuticals Corp

12d ago, source: Reuters

Adamis Pharmaceuticals Corporation is a specialty biopharmaceutical company. The Company is focused on developing and commercializing products in various therapeutic areas, including allergy ...

Adamis Pharmaceuticals Corporation (ADMP) Q3 2022 Earnings Call Transcript

24d ago, source: Seeking Alpha

Good afternoon, ladies and gentlemen, and welcome to the Adamis Pharmaceuticals' Third Quarter 2020 Financial Results Conference Call. [Operator Instructions]. This call is being recorded on ...

Adamis Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update

24d ago, source: Yahoo

SAN DIEGO, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company primarily focused on developing and commercializing ...

Adamis: Q3 Earnings Snapshot

24d ago, source: SFGate

SAN DIEGO (AP) _ Adamis Pharmaceuticals Corp. (ADMP) on Monday reported a loss of $4.4 million in its third quarter. The San Diego-based company said it had a loss of 3 cents per share.

What Are Adamis Pharmaceuticals Corporation’s Short-Term Prospects?

9d ago, source:

Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) price is hovering higher on Tuesday, November 29, jumping 5.33% above its previous close. A look at today’s price movement shows that the recent level ...

Liminatus Pharma LLC and Iris Acquisition Corp to combine to incorporate and accelerate much-needed cancer treatments

8d ago, source: newsroom.businesswire.com

Iris Parent Holding Corp (“ParentCo”), to be renamed Liminatus Pharma, Inc. at the closing, intends to file a registration statement on Form S-4 (as it may be amended from time to time ...

TNXP Tonix Pharmaceuticals Holding Corp.

9d ago, source: Seeking Alpha

The chart has 1 X axis displaying Time. Data ranges from 2021-11-26 00:00:00 to 2021-11-26 00:00:00. The chart has 1 Y axis displaying values. Data ranges from -0.5 to 0.5.

Adamis Pharmaceuticals Corporation: Adamis Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update

23d ago, source: Finanznachrichten

ADAMIS PHARMACEUTICALS CORPORATION AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS DATA (Unaudited) Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...